ATE308756T1 - Verfahren zur unterscheidung von prostatakrebs und gutartiger prostatahyperplasie - Google Patents

Verfahren zur unterscheidung von prostatakrebs und gutartiger prostatahyperplasie

Info

Publication number
ATE308756T1
ATE308756T1 AT00922118T AT00922118T ATE308756T1 AT E308756 T1 ATE308756 T1 AT E308756T1 AT 00922118 T AT00922118 T AT 00922118T AT 00922118 T AT00922118 T AT 00922118T AT E308756 T1 ATE308756 T1 AT E308756T1
Authority
AT
Austria
Prior art keywords
prostate
prostate cancer
differentiation
benefits
bph
Prior art date
Application number
AT00922118T
Other languages
German (de)
English (en)
Inventor
Stephen Mikolajczyk
Tang Wang
Harry Rittenhouse
Robert Wolfert
Kevin Slawin
Original Assignee
Hybritech Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc, Baylor College Medicine filed Critical Hybritech Inc
Application granted granted Critical
Publication of ATE308756T1 publication Critical patent/ATE308756T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT00922118T 1999-04-30 2000-04-12 Verfahren zur unterscheidung von prostatakrebs und gutartiger prostatahyperplasie ATE308756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/303,339 US6423503B1 (en) 1999-04-30 1999-04-30 Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
PCT/US2000/009789 WO2000067030A1 (en) 1999-04-30 2000-04-12 Method to distinguish prostate cancer from benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
ATE308756T1 true ATE308756T1 (de) 2005-11-15

Family

ID=23171625

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922118T ATE308756T1 (de) 1999-04-30 2000-04-12 Verfahren zur unterscheidung von prostatakrebs und gutartiger prostatahyperplasie

Country Status (8)

Country Link
US (1) US6423503B1 (enExample)
EP (1) EP1175619B1 (enExample)
JP (1) JP4447796B2 (enExample)
AT (1) ATE308756T1 (enExample)
AU (1) AU776578B2 (enExample)
CA (1) CA2370290C (enExample)
DE (1) DE60023683T2 (enExample)
WO (1) WO2000067030A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534001A (ja) * 2000-05-24 2003-11-18 エフ．ホフマン−ラ ロシュ アーゲー プロｐｓａの特定形態に対する抗体およびそのイムノアッセイにおける使用
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
US20050037447A1 (en) * 2003-07-08 2005-02-17 Yong-Chuan Wong Protein markers for human benign prostatic hyperplasia (BPH)
AU2005220980A1 (en) * 2004-03-11 2005-09-22 Baylor College Of Medicine Method to predict risk of BPH progression
US20090088981A1 (en) * 2007-04-26 2009-04-02 Neville Thomas B Methods And Systems Of Dynamic Screening Of Disease
GB2464032A (en) * 2008-05-15 2010-04-07 Soar Biodynamics Ltd Methods and systems for integrated health systems
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US20100168621A1 (en) * 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US8666961B1 (en) * 2010-03-19 2014-03-04 Waheed Qureshi Platform for generating, managing and sharing content clippings and associated citations
CA2853705C (en) 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5858685A (en) 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
WO1998049323A1 (en) * 1997-04-30 1998-11-05 Hybritech Incorporated Forms of prostate specific antigen and methods for their detection
US6300088B1 (en) * 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen

Also Published As

Publication number Publication date
WO2000067030A1 (en) 2000-11-09
CA2370290C (en) 2012-01-17
EP1175619A1 (en) 2002-01-30
US6423503B1 (en) 2002-07-23
JP2002543431A (ja) 2002-12-17
CA2370290A1 (en) 2000-11-09
EP1175619B1 (en) 2005-11-02
DE60023683T2 (de) 2006-06-01
AU776578B2 (en) 2004-09-16
DE60023683D1 (de) 2005-12-08
AU4235400A (en) 2000-11-17
JP4447796B2 (ja) 2010-04-07

Similar Documents

Publication Publication Date Title
DE60023683D1 (de) Verfahren zur unterscheidung von prostatakrebs und gutartiger prostatahyperplasie
IS5093A (is) Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli
ATE335814T1 (de) Modifizierte arginindeaminase
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
EA199900428A1 (ru) Конъюгаты, используемые в лечении рака предстательной железы
WO2004086949A3 (en) Dna markers for management of cancer
CY1108563T1 (el) Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
WO2001025791A3 (en) Prostate cancer marker proteins
ATE361075T1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
NO995518D0 (no) Arylsubstituerte piperaziner brukbare ved behandling av benign prostatisk hyperplasi
NO20004141D0 (no) Nye substituerte pyridinoarylpiperaziner er anvendelige ved behandling av benign prostatahyperplasi
WO2002044417A3 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
WO2002044420A3 (en) Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
GB2418985B (en) Protein markers for human benign prostatic hyperplasia(BPH)
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
AU2002336520A1 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
Coune et al. Proteolytic and fibrinolytic factors in the human prostate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties